NUVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. NUVA has a medium profitability rating, but doesn't score so well on its financial health evaluation. NUVA has a correct valuation and a medium growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

NUVA had positive earnings in the past year.
NUVA had a positive operating cash flow in the past year.

1.2 Ratios

The Return On Assets of NUVA (1.36%) is better than 75.38% of its industry peers.
NUVA has a better Return On Equity (3.19%) than 76.38% of its industry peers.
The Return On Invested Capital of NUVA (3.43%) is better than 76.38% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NUVA is significantly below the industry average of 8.81%.
The last Return On Invested Capital (3.43%) for NUVA is above the 3 year average (2.87%), which is a sign of increasing profitability.

		Industry Rank	Sector Rank
ROA	1.36%
ROE	3.19%
ROIC	3.43%

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)2.87%

ROIC(5y)3.87%

1.3 Margins

With a decent Profit Margin value of 2.32%, NUVA is doing good in the industry, outperforming 74.37% of the companies in the same industry.
NUVA's Profit Margin has declined in the last couple of years.
NUVA has a better Operating Margin (6.73%) than 74.87% of its industry peers.
In the last couple of years the Operating Margin of NUVA has declined.
NUVA has a Gross Margin of 71.66%. This is amongst the best in the industry. NUVA outperforms 82.41% of its industry peers.
NUVA's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	6.73%
PM (TTM)	2.32%
GM	71.66%

OM growth 3Y-12.51%

OM growth 5Y-9.94%

PM growth 3Y-15.55%

PM growth 5Y-15.81%

GM growth 3Y-0.57%

GM growth 5Y-0.5%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NUVA is destroying value.
The number of shares outstanding for NUVA has been increased compared to 1 year ago.
The debt/assets ratio for NUVA has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 1.91 indicates that NUVA is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of NUVA (1.91) is comparable to the rest of the industry.
NUVA has a Debt/Equity ratio of 0.89. This is a neutral value indicating NUVA is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.89, NUVA is not doing good in the industry: 78.89% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.89
Debt/FCF	N/A
Altman-Z	1.91

ROIC/WACC0.42

WACC8.11%

2.3 Liquidity

A Current Ratio of 1.25 indicates that NUVA should not have too much problems paying its short term obligations.
With a Current ratio value of 1.25, NUVA is not doing good in the industry: 89.45% of the companies in the same industry are doing better.
A Quick Ratio of 0.65 indicates that NUVA may have some problems paying its short term obligations.
With a Quick ratio value of 0.65, NUVA is not doing good in the industry: 93.97% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.25
Quick Ratio	0.65

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.61% over the past year.
The Earnings Per Share has been growing slightly by 0.62% on average over the past years.
NUVA shows a small growth in Revenue. In the last year, the Revenue has grown by 4.44%.
Measured over the past years, NUVA shows a small growth in Revenue. The Revenue has been growing by 3.20% on average per year.

EPS 1Y (TTM)15.61%

EPS 3Y-7.23%

EPS 5Y0.62%

EPS Q2Q%19.15%

Revenue 1Y (TTM)4.44%

Revenue growth 3Y0.96%

Revenue growth 5Y3.2%

Sales Q2Q%2.36%

3.2 Future

Based on estimates for the next years, NUVA will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.32% on average per year.
NUVA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.89% yearly.

EPS Next Y13.97%

EPS Next 2Y14.82%

EPS Next 3Y14.9%

EPS Next 5Y14.32%

Revenue Next Year6.01%

Revenue Next 2Y6.22%

Revenue Next 3Y6.45%

Revenue Next 5Y6.89%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 19.88 indicates a rather expensive valuation of NUVA.
Based on the Price/Earnings ratio, NUVA is valued cheaply inside the industry as 86.93% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 28.39. NUVA is valued slightly cheaper when compared to this.
NUVA is valuated correctly with a Price/Forward Earnings ratio of 15.23.
88.44% of the companies in the same industry are more expensive than NUVA, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of NUVA to the average of the S&P500 Index (25.72), we can say NUVA is valued slightly cheaper.

		Industry Rank	Sector Rank
PE	19.88
Fwd PE	15.23

4.2 Price Multiples

93.47% of the companies in the same industry are more expensive than NUVA, based on the Enterprise Value to EBITDA ratio.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	11

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as NUVA's earnings are expected to grow with 14.90% in the coming years.